In 1986, a 26-year-old female had been diagnosed as having Graves' disease and had been treated with methimazole for four months. After the treatment with propylthiouracil for another four months, she had been treated with methimazole once again. She was in complete remission for two years. She again experienced symptoms of hyperthyroidism, and treatment with methimazole was started again. On t...

Here in this paper, we report a 31-year-old case admitted with symptoms of hyperthyroidism that was then diagnosed with Grave's disease (GD) and underwent treatments with a low dosage of methimazole (10 mg/day). 20 days after treatments initiations, she developed antithyroid arthritis syndrome. This patient experienced arthritis and arthralgia in at least 4 joints. And all autoimmune and microb...

The choice of therapeutic strategies for hyperthyroidism during pregnancy is limited. Surgery and radioiodine are typically avoided, leaving propylthiouracil and methimazole in the US. Carbimazole, a metabolic precursor of methimazole, is available in some countries outside of the US. In the US propylthiouracil is recommended because of concern about developmental toxicity from methimazole and ...

the glucosinolate autolysis products of crushed seeds of desclirainia sophia l. (khakeshi) and brassica napus l. (shelghem) were administered orally to rats in doses representing 8,16 and 32 gm seeds/kg body weight/day at intervals of 10, 20 and sometimes 30 days. serum t3 and t4 concentrations were reduced in 10 day•autolysate treated animals in a similar fashion to that found with methimazole...

Objective Comparison of studies on remission rates in pediatric Graves’ disease is complicated by lack uniformity treatment protocols, definition, and follow-up duration. We performed a systematic review attempted to create recalculating based an intention-to-treat analysis. Methods PubMed Embase were searched August 2020 for patients with disease: (i) 2 18 years age, (ii) initially treated met...

INTRODUCTION Radioactive iodine ((131)I) is widely prescribed for treatment of Graves' disease. A dose of 370 to 555 MBq (10 to 15 mCi) is usually enough, but reports of improved remission rates with single doses up to 20-30 mCi, and 38.5 mCi at most, exist. CASE PRESENTATION A 53-year-old male patient was evaluated in September 2005, with symptoms of thyrotoxicosis for 2 years. He presented ...

Dear Editor, We read with great interest the article by Kim et al. (1), “Novel application of quantitative single-photon emission computed tomography/computed tomography to predict early response to methimazole in Graves’ disease?” In the present article, the authors developed Cox regression prediction models to investigate the independent predictive factors associated with achievement of euthy...

UNLABELLED Our objective was to compare, over a time-course, markers of oxidative stress, the REDOX environment, and the antioxidant enzymatic system in the liver of rats with methimazole- or thyroidectomy-caused hypothyroidism. METHODS We used 60 male Wistar rats divided into four groups: 1) the euthyroid, which received only tap water, 2) false thyroidectomy, which received the surgery and ...

RATIONALE Treatment choices are limited, when deciding how to manage thyrotoxicosis and moderate to severe Graves ophthalmopathy (GO) with suspected optic nerve damage in patients with elevated liver transaminase levels. The situation become even more complicated, if methimazole induced hepatotoxicity is suspected and intravenous methylprednisolone is co-administrated. PATIENT CONCERNS A 74-y...

Methimazole is used as an antithyroid drug to control the symptoms of hyperthyroidism and maintain patients in a euthyroid state. Administration of this drug is associated with agranulocytosis and hepatotoxicity, which are the two most significant adverse effects. The present investigation was conducted to study the protective role of taurine against cytotoxicity induced by methimazole and its ...